A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl
A phase 3 trial of Sacituzumab tirumotecan, Bevacizumab, Dexamethasone in ovarian cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) is a phase 3 interventional study registered as NCT06824467 by Merck Sharp & Dohme LLC, with 770 participants planned, started 2025-04-09 and due to reach its primary completion in 2029-04-27. Interventions recorded: Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent). Conditions listed: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Shares Sacituzumab tirumotecan, Bevacizumab, Merck & Co. (MSD), Ovarian cancer.
- TrialA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Shares Sacituzumab tirumotecan, Dexamethasone, Merck & Co. (MSD).
- TrialSacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A
Shares Sacituzumab tirumotecan, Dexamethasone, Merck & Co. (MSD).
- TrialA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD).
- TrialPembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
Shares Sacituzumab tirumotecan, Dexamethasone, Merck & Co. (MSD).
- TrialA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc
Shares Sacituzumab tirumotecan, Bevacizumab, Merck & Co. (MSD).
- TrialMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal C
Shares Bevacizumab, Ovarian cancer.
- TrialSacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P
Shares Sacituzumab tirumotecan, Merck & Co. (MSD).